In 2013, “biosimilars” were a hot topic at the Arizona Legislature. In the end, the bill to define the classes of biosimilars in Arizona statute along with the the process for substitution did not move forward to the floor as key stateholders and legislators continued to research and discuss the issue.
It is expected that the first biosimilars will be approved by the FDA in 2015 and that the states that have yet to up date their pharmacy acts (including Arizona) will be opening up these discussions again.Continue reading